129 related articles for article (PubMed ID: 34185084)
21. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
[TBL] [Abstract][Full Text] [Related]
22. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
23. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
24. Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial.
Martelletti P; Barbanti P; Grazzi L; Pierangeli G; Rainero I; Geppetti P; Ambrosini A; Sarchielli P; Tassorelli C; Liebler E; de Tommaso M;
J Headache Pain; 2018 Nov; 19(1):101. PubMed ID: 30382909
[TBL] [Abstract][Full Text] [Related]
25. Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.
Rapoport AM; Lin T; Tepper SJ
Headache; 2020 Jan; 60(1):229-234. PubMed ID: 31913517
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
[TBL] [Abstract][Full Text] [Related]
27. Drugs for the acute treatment of migraine in children and adolescents.
Richer L; Billinghurst L; Linsdell MA; Russell K; Vandermeer B; Crumley ET; Durec T; Klassen TP; Hartling L
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD005220. PubMed ID: 27091010
[TBL] [Abstract][Full Text] [Related]
28. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
29. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
Visser WH; Winner P; Strohmaier K; Klipfel M; Peng Y; McCarroll K; Cady R; Lewis D; Nett R;
Headache; 2004 Oct; 44(9):891-9. PubMed ID: 15447698
[TBL] [Abstract][Full Text] [Related]
30. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
[TBL] [Abstract][Full Text] [Related]
31. Device profile of the Nerivio™ for acute migraine treatment: overview of its efficacy and safety.
Rapoport AM; Lin T
Expert Rev Med Devices; 2019 Dec; 16(12):1017-1023. PubMed ID: 31747304
[No Abstract] [Full Text] [Related]
32. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Seeburger JL; Taylor FR; Friedman D; Newman L; Ge Y; Zhang Y; Hustad CM; Lasorda J; Fan X; Hewitt D; Ho T; Connor KM
Cephalalgia; 2011 May; 31(7):786-96. PubMed ID: 21078681
[TBL] [Abstract][Full Text] [Related]
34. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study.
Gawel M; Aschoff J; May A; Charlesworth BR;
Headache; 2005 Jan; 45(1):7-16. PubMed ID: 15663607
[TBL] [Abstract][Full Text] [Related]
35. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
Lipton RB; Dodick DW; Ailani J; Lu K; Finnegan M; Szegedi A; Trugman JM
JAMA; 2019 Nov; 322(19):1887-1898. PubMed ID: 31742631
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.
Tuchman M; Hee A; Emeribe U; Silberstein S
CNS Drugs; 2006; 20(12):1019-26. PubMed ID: 17140280
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
38. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Winner P; Rothner AD; Wooten JD; Webster C; Ames M
Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
[TBL] [Abstract][Full Text] [Related]
39. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
[TBL] [Abstract][Full Text] [Related]
40. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]